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Aim:  It is still  unclear  whether  telemonitoring  reduces  hospitalization  and  mortality  in heart  failure  (HF)
patients and  whether  adding  an  Information  and  Computing  Technology-guided-disease-management-
system  (ICT-guided-DMS)  improves  clinical  and patient  reported  outcomes  or reduces  healthcare  costs.
Methods: A multicenter  randomized  controlled  trial  was  performed  testing  the effects  of INnovative  ICT-
guided-DMS  combined  with  Telemonitoring  in  OUtpatient  clinics  for Chronic  HF  patients  (IN  TOUCH)
with  in total  179  patients  (mean  age  69  years;  72%  male;  77%  in New  York  Heart  Association  Classiﬁcation
(NYHA)  III–IV; mean  left ventricular  ejection  fraction  was 28%).  Patients  were  randomized  to  ICT-guided-
DMS  or  to ICT-guided-DMS  + telemonitoring  with  a follow-up  of  nine  months.  The composite  endpoint
included  mortality,  HF-readmission  and  change  in  health-related  quality  of  life  (HR-QoL).
Results:  In total  177  patients  were  eligible  for analyses.  The  mean  score  of  the  primary  composite  endpoint
was  −0.63  in ICT-guided-DMS  vs. −0.73 in  ICT-guided-DMS  + telemonitoring  (mean  difference  0.1,  95%
CI:  −0.67  +0.82,  p =  0.39).  All-cause  mortality  in  ICT-guided-DMS  was  12%  versus  15% in  ICT-guided-
DMS +  telemonitoring  (p = 0.27);  HF-readmission  28%  vs. 27%  p  = 0.87;  all-cause  readmission  was  49%
vs.  51%  (p = 0.78).  HR-QoL  improved  in  most  patients  and  was  equal  in  both  groups.  Incremental  costs
were D  1360  in favor  of  ICT-guided-DMS.  ICT-guided-DMS  +  telemonitoring  had  signiﬁcantly  fewer  HF-
outpatient-clinic  visits  (p  <  0.01).
Conclusion:  ICT-guided-DMS  + telemonitoring  for the management  of  HF  patients  did  not affect  the  pri-
mary  and  secondary  endpoints.  However,  we  did  ﬁnd  a reduction  in  visits  to  the  HF-outpatient  clinic  in
this  group  suggesting  that  telemonitoring  might  be safe  to use  in reorganizing  HF-care  with relatively
low  costs.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Increasing shortage of resources, growing costs, increase in
xpensive treatments and downwards pressure on healthcare bud-
ets, necessitates a thorough review of management of patients
ith heart failure (HF). Heart failure is a chronic debilitating con-
ition with a poor prognosis and can be deﬁned as an abnormality
∗ Corresponding author at: University of Groningen, University Medical Center
roningen, Department of Cardiology, HPC AB 41, PO Box 30.001, 9700 RB Gronin-
en, The Netherlands. Fax: +31 50 3618062.
E-mail address: i.h.kraai@umcg.nl (I. Kraai).
ttp://dx.doi.org/10.1016/j.ijmedinf.2015.10.001
386-5056/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open acce
y-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of the cardiac structure or function leading to failure of the heart to
deliver oxygen and causes a cascade of syndromes, symptoms and
complaints [1]. A ﬁrst step in efﬁciently organizing HF-care was
taken by implementing specialized HF-outpatient clinics, with a
strong collaboration between HF-nurses and cardiologists [2,3]. In
these HF-outpatient clinics, Disease Management Programs (DMP)
were introduced [4,5] and over the last decade, these clinics became
‘care as usual’ in several European countries [6]. The effect on qual-
ity of care and clinical outcomes in HF-clinics in the Netherlands
was investigated by two randomized studies [7,8]. Although both
studies have contributed to the quality of DMP in HF-outpatient
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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linics led by specialized HF-nurses, the key characteristics of
atients who beneﬁts most from a DMP  remained unclear [9].
Although tele cardiology seems to be a large success for the
anagement of pace-makers and deﬁbrillators, the use of tele
ardiology in the follow-up of technological functioning of pace-
akers and deﬁbrillators is quite different from the use in the
onitoring of symptoms of deterioration in patients. Guidelines
uggest to include careful monitoring of HF patients in addition
o regular outpatient clinic visits by means of telephonic assess-
ents or telemonitoring [1]. On a caregiver level, cardiologists and
F-nurses have high expectations of telemonitoring by expecting
t to improve quality of care, reduce costs and improves patients’
ealth-Related Quality of Life (HR-QoL) by increasing feelings of
ontrol and empowerment of the patient [10]. On the other side, the
isalignment between patients expectations regarding the contin-
ously monitoring of the data and the actually non-continuously
onitoring activities from the professionals providing the ser-
ice is a cause of concern. On a patient level, patients experience
y using telemonitoring an increase in their self-care activities
11], an increase in their understanding of HF symptoms and an
mprovement in their feeling of safety [12]. Furthermore, patients
xperience a high level of satisfaction with telemonitoring and
ave the feeling that care-givers continuously monitor the trans-
itted parameters (despite the knowledge that monitoring by
are-givers is non-continuously) [13]. On a population level, results
egarding reduction in hospitalization and mortality rates by the
se of telemonitoring in HF patients compared to usual care are
mbiguous [14–19]. It is suggested that the development of tools
o automatically analyze the data and provide advice to patients
nd caregivers regarding the treatment of the patient would be a
evolution [18]. However, until now it is not clear whether tele-
onitoring, when delivered as an integrated approach added to an
nformation and communication technology guided disease man-
gement system (ICT-guided-DMS), improves clinical and patient
eported outcomes or reduces healthcare costs. The value of a
omputer Decision Support System (CDSS) incorporated into an
CT-guided-DMS to facilitate healthcare professionals into optimiz-
ng treatment and care is also not known. Therefore, the aim of this
tudy is to assess the effect of telemonitoring on top of an ICT-
uided-DMS with an CDSS in patients with worsening HF on the
ombined endpoint of death, readmission and HR-QoL, compared
o patients treated with ICT-guided-DMS and CDSS alone.
. Methods
.1. IN TOUCH study
The IN TOUCH (the value of INnovative ICT-guided disease man-
gement combined with Telemonitoring in OUt patient clinics for
hronic Heart failure patients) was a multicenter, randomized
ontrolled study designed to investigate the effects and costs of
CT-guided-DMS with CDSS, versus ICT-guided-DMS with CDSS and
elemonitoring in HF-patients on a composite endpoint of mortal-
ty, HF-readmission and change in HR-QoL. The rational and design
ave been described elsewhere [20]. In short, the study consisted
f one control group and two intervention groups. The control
roup consisted of separate hospitals in which patients received
sual care without any use of telemonitoring devices for the entire
tudy. The intervention group consisted of one group receiving ICT-
uided-DMS with CDSS without telemonitoring, the other group
eceived ICT-guided-DMS with CDSS and telemonitoring, from now
n described as ICT-guided-DMS group and telemonitoring group
espectively. In December 2010, adjustments to the study proto-
ol were necessary for two reasons. It was impossible to recruit
ospitals for the usual care part of the study (the control group)dical Informatics 85 (2016) 53–60
because using any form of telemonitoring in the control group
during the complete study period was an exclusion criterion to
participate as a control hospital in this study. The second reason
for the adjustment of the study protocol was the low inclusion rate
of patients with an HF-admission in the intervention hospitals. The
adjustments to the study protocol were (1) to have a randomized
intervention study without control group and (2) broadening of the
inclusion criteria to inclusion of patients with HF-deterioration vis-
iting the HF clinic and outpatient HF clinic and needed to be treated
with extra diuretics. In addition, the inclusion period was  extended
with nine months. As a result of this the study design changed
from a study with 3 arms (a control group and two  intervention
groups) to a study with 2 intervention arms and no control group.
Patients were recruited in ten Dutch hospitals during a period of
in total 25 months (December 2009–January 2012). The medical
ethical committee approved the protocol and the adjustments to
the protocol which had no consequences for the feasibility of the
ongoing study (ABR:NL26271.042.08). All patients provided writ-
ten informed consent and our study conforms to the principles
outlined in the Declaration of Helsinki.
2.2. Patient population
All included patients had worsening HF based on typical signs
and symptoms of ﬂuid retention. Inclusion criteria were: admis-
sion to the intensive care/ coronary care unit or cardiology ward
or visiting the outpatient HF-clinic and in need of treatment or
adjustment with oral or intravenous diuretics, aged 18 years or
older, evidence of structural underlying heart disease, documented
reduced left ventricular ejection fraction (LVEF) ≤45%. Exclusion
criteria were: myocardial infarction in the last month, cardiac inva-
sive intervention in the past 6 months or planned in the next 3
months, hemodialysis, use of other telemonitoring systems, inabil-
ity or unwillingness to give informed consent.
2.3. Randomization
Randomization to one of the intervention groups was per-
formed within 2 weeks after inclusion. One group received
ICT-guided-DMS, the other group received telemonitoring. The
computer-generated randomization scheme used random per-
muted blocks of 2:1 (original protocol) and 1:1 (adjusted protocol
December 2010) stratiﬁed by centre to ensure balanced assignment
of patients to each group in the ten participating centres.
2.4. Intervention
2.4.1. ICT-guided-DMS
All patients in both groups. The function of the CDSS in the
DMS  was  to provided advice to the healthcare providers accord-
ing to the actual ESC-HF guidelines, regarding the up-titration of
HF-medication to optimal individual doses. The ESC-HF guidelines
were programmed into the DMS  as workable digital ﬂow-charts.
The advice of the CDSS was  based on the input of data from nursing
assessment, physical examination, medical history, laboratory and
questionnaires; if for example the vital signs and laboratory val-
ues of the patient were within the pre-deﬁned ranges of the digital
ﬂow-chart, the CDSS generated an advice to further up-titrate the
medication to optimal doses according to the HF-guidelines. The
data regarding the nursing assessment, physical examination and
medical history was added manually to the system by the nurse.
The data regarding the laboratory system was loaded into the CDSS
automatically. The questionnaires could be presented to the patient
electronically or on paper. If the questionnaire was ﬁlled in by the
patient electronically, the data was loaded into the CDSS automat-
ically. If the questionnaire was ﬁlled in by the patient on paper, the
l of Medical Informatics 85 (2016) 53–60 55
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Table 1
Scoring system for the primary composite endpoint [25].
End point Score
Death (at any time during study) −3
Survival to end of study 0
First readmission for heart failure during the study period −1
No  readmission for heart failure during the study period 0
Change in quality of life at 9 months:
• Improvement ≥20 units +2
•  Improvement by 10 until 19 units +1
•  No improvement by −9 until +4 units 0
• Worsening by +5 until +9 units −1I. Kraai et al. / International Journa
ata was entered into the CDSS manually by the nurse. Further-
ore, the data from the health-monitor loaded automatically into
he CDSS. Both groups received counselling on HF-symptom man-
gement and improvement of the non-pharmacological regimen
ased on protocols and recent HF-guidelines [20]. Patients allocated
o the telemonitoring group were only allowed to visit the cardi-
logist or HF-nurse in case of an absolute need for intervention.
he ICT-guided-DSM group followed the normal HF-routine of the
ndividual hospitals, like any other HF-patient, without limitations
o the visits.
.4.2. Telemonitoring
Patients in the telemonitoring group received telemonitoring
evices at home consisting of a weighing scale, blood pressure
quipment, an ECG-device and a health-monitor. The instruction
as to record weight and blood pressure once a day and an ECG
n case of starting or up-titration of Beta-blockers. The health-
onitor was an interactive monitor which received the data from
he weighing scale, blood pressure equipment and if applicable the
CG-device automatically at the end of the measurement by means
f a wireless bluetooth connection. After receiving the data from the
bove mentioned devices, the health-monitor generated standard
ealth-related questions regarding the patients’ health status. The
F-nurse could add pre-deﬁned and individual ranges of weight,
lood pressure or heart rhythm in the CDSS. In case of deviation of
he pre-deﬁned ranges the health-monitor at home generated auto-
atically supplementary questions to evaluate the actual health
ituation. The data of the weighing scale, blood pressure equip-
ent and if applicable the ECG-device and the answers on the
ealth-related questions were directly transmitted by the health-
onitor through the GPRS network to the DMS  system located in
he hospital and loaded in the CDSS. In case of deviation of the pre-
eﬁned ranges the HF-nurse was informed automatically by mobile
hone and email (according to the study protocol). To prevent an
ncreased workload for the HF-nurse and to prevent an incorrect
erception of the patient that the telemonitoring measurements
ere continuously monitored, the patients were informed that they
ad to perform the measurement every morning (including the
eekends) before a certain time. If there was a deviation of the
re-deﬁned ranges, the HF-nurse contacted the patient within two
ours and discussed the symptoms and treatment with the patient
21].
.5. Data collection
The change in HR-QoL between baseline and the end of the
tudy was assessed by the Minnesota Living with HF Question-
aire (MLHFQ). The MLHFQ is a 21-item disease-speciﬁc HR-QoL
nstrument with scores for each item ranging from 0 to 5, a sum-
ary score ranging from 0 to 105 and 2 subscales. Higher scores
epresents worse HR-QoL [22].
Data on hospitalizations and mortality were collected from the
edical records during the 9 months of follow-up. The reason of
ospital readmission or death and the date of the event were adju-
icated by an independent endpoint committee blinded for the
roup assignment. The days lost to death were deﬁned as the num-
er of days lost because of death during the 9 months of follow-up.
Data on costs; for the cost minimization analyses a distinc-
ion was made between intervention costs and resource utilization
osts. Data on resource use were collected from medical records and
uestionnaires. The cost of the intervention was deﬁned as the costs
f the ICT-guided-DMS with CDSS, the costs of the telemonitoring
evices and handling of the alarms (personnel) and were calculated
s a ﬁxed price over the follow-up period. Resource utilization costs
ere calculated by collecting data on scheduled and non-scheduled
utpatient clinic visits and hospital admissions (HF and non-HF-•Worsening by ≥10 units −2
Possible score −6 to +2
related). In addition, a patient MTA-questionnaire adapted from the
iMTA/TiC-P [23] was administered at 4.5 and 9 months follow-up to
collect complementary data (e.g., GP, dietician, physiotherapist vis-
its, home care, and nursing home [day care, and admissions]). Unit
costs were estimated by using the Dutch guidelines for cost studies
[24] and inﬂated to the price level of 2012 using a general consumer
price index (http://www.CBS.nl). The time horizon of the cost anal-
ysis was  9 months. Indirect costs, such as productivity losses, were
not calculated.
2.6. Endpoints
The primary endpoint was  a composite weighted score consist-
ing of a value for mortality, HF-readmission and change in HR-QoL
between baseline and end of study measured with the MLHFQ
with a possible range of –6 to +2. A HF-readmission was deﬁned
as an unplanned overnight hospital stay due to progression of HF
or directly related to HF. The scoring system of the primary com-
posite endpoint was adapted from the A-HeFT study [25] (Table 1).
The endpoint has been used in several other studies and is also rec-
ommended in a recent statement by the Heart Failure Association
[26]. In case of missing data for the primary composite endpoint,
the worst-case scenario was  used for the analyses. Patients lost to
follow-up were assumed to have died (−3), and patients without
a HR-QoL score received the worst score for that component (−2).
Secondary endpoints of the study were the separate components
of the primary endpoint (mortality, HF-readmission and change in
HR-QoL). Other major secondary endpoints were the total num-
ber and duration of all hospital admissions, number of visits to the
outpatient HF-clinic and cost analyses.
2.7. Sample size
We expect with 80% power to detect superiority for telemon-
itoring using a one-sided, two-sample t-test, when 130 patients
are included in the telemonitoring group and 90 patients in the
ICT-guided-DMS group. The true difference between both groups
was assumed to be 0.8 regarding the primary composite endpoint
score. The largest difference between both groups was expected to
be observed in the HR-QoL domain.
2.8. Statistical analyses
All analyses were conducted according to the intention-to-treat
principle (n = 177). Descriptive statistics, independent t-tests in
case of normal distributions, Mann–Whitney U-tests in case of
skewed distributions for continuous variables and Chi-square tests
for categorical variables were used to compare the demographic
and clinical characteristics between both groups. To compare
the primary composite endpoint score between both groups a
5 l of Medical Informatics 85 (2016) 53–60
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Table 2
Baseline characteristics of the patients according to the assigned treatment (n = 177).
ICT DMS n = 83 ICT DMS with
TM n = 94
p-Value
Demographics
Age (yrs) 69
± 11
69
± 12
0.98
Male sex 62 (75) 66 (70) 0.51
LVEF% 28
± 9.0
27
± 9.9
0.57
Duration of diagnosis HF (yrs) 4.6
±  5.6
5.5
± 6.5
0.41
New diagnosis of HF 25 (30) 29 (31) 0.92
Etiology
Ischemic 35 (42) 45 (48) 0.45
History of myocardial infarction 25 (30) 35 (37) 0.32
Co-morbidities
Hypertension 29 (35) 26 (28) 0.30
COPD  17 (21) 21 (22) 0.76
Atrial  ﬁbrillation 32 (40) 47 (48) 0.13
Diabetes 29 (35) 32 (34) 0.26
Stroke 6 (7) 12 (13) 0.22
Oncology 12 (15) 12 (13) 0.74
Clinical variables
NYHA classiﬁcation 0.92
II 18 (22) 21 (23)
III  49 (60) 51 (57)
IV  15 (18) 18 (20)
Heart  rate (bpm) 84
± 20
81
± 19
0.42
Weight (kg) 84
± 18
81
± 17
0.40
LBTB 16 (19) 31 (33) 0.04
SBP  (mmHg) 123
± 21
117
± 20
0.09
DBP (mmHg) 74
± 13
71
± 11
0.06
Cardiovascular interventions
CABG 15 (18) 22 (23) 0.38
PCI  13 (16) 18 (19) 0.54
ICD  (CRT not included) 10 (12) 16 (17) 0.35
Laboratory
Hemoglobin, mmol/L 8.36
± 0.98
8.24
± 1.16
0.52
Sodium, mmol/L 141
± 3.07
141
± 4.33
0.94
Creatinine, mol/L 135
± 70.4
134
± 64.7
0.90
Nt-pro BNP, ng/L 3672
(384–22929)
4394
(598–28887)
0.34
Mean Egfr, mL/min/1.73 m2 66.3
± 26.6
65.3
± 29.8
0.82
Medication
Diuretica 69 (89) 72 (87) 0.74
ACE-inhibitor 46 (59) 50 (60) 0.87
Angiotensin receptor blocker 21 (27) 20 (24) 0.68
Beta  blocker 54 (69) 53 (64) 0.47
Aldosteron antagonist 45 (58) 49 (59) 0.86
Note: values are given as mean ± SD, number (percentage), or median (25–75 per-
centiles).
Variables were tested two-sided.
ICT DMS  = ICT-guided-disease management system with computer decision sup-
port.
ICT  DMS  with TM = ICT-guided-disease management system with computer deci-
sion  support and telemonitoring.
yrs = years; LVEF = left ventricular ejection fraction; HF = heart failure; NYHA = New
York Heart Association; bpm = beats per minute; kg = kilograms; LBTB = left bun-
dle branch block; SBP = systolic blood pressure; DBP = diastolic blood pressure;6 I. Kraai et al. / International Journa
ne-sided two-sample t-test was performed and 95% conﬁdence
ntervals were constructed to describe the treatment differences.
aplan Meier curves were constructed for the differences in time to
ortality between both groups. Costs per category were calculated
y multiplying resource use with the cost per item. Means per
roup and incremental costs were calculated based on the trial
ata. Bootstrap simulations (5000 replications of the trial data)
ere performed to estimate the conﬁdence intervals surrounding
he incremental costs (2.5th and 97.5th percentile). The cost data
or hospital admissions were highly skewed due to one patient with
n extreme admission duration (126 days) therefore, we  performed
his analysis whereby the mean admission duration for this patient
as replaced with the group mean value. Analyses were performed
sing PASW-version 18.0, Excel-version 2003 and R-version 2.15.1.
. Results
Overall, 179 patients were randomized into the study. Two
atients did not fulﬁl the inclusion criterion of worsening HF and
ere therefore not part of the analysis. In total, 177HF-patients
ere analyzed, of which 83 patients were randomized into the ICT-
uided-DMS group and 94 patients to the telemonitoring group.
wenty-three patients (13%) were included from the outpatient HF-
linic, the others from a hospital admission for HF. The distribution
f the number of patients in both groups was not equal, due to the
esign of the study (see power analysis) and the forced adjustment
f the study protocol (change in randomization blocks).
.1. Patient characteristics
Overall, the mean age of the patients was 69 (±12) years, 72%
as male (n = 128) and the mean LVEF was 28% (±9%). During inclu-
ion most patients (77%, n = 133) were classiﬁed as NYHA III–IV
hile 23% (n = 39) were in NYHA II. In total 31% of the patients
n = 54) were newly diagnosed with HF (diagnosis <6 months), the
verage period diagnosed with HF was 4.6 years for the ICT-guided-
MS group and 5.5 years for the telemonitoring group (p = 0.41).
ther baseline characteristics such as co morbidity and prescribed
edication were comparable between both groups (Table 2). The
dherence of the patients to telemonitoring (assessed by daily
eighing and measuring of blood pressure) had a median of 95%
ith a range from 87 to 99% for the total study period (not shown).
.2. Primary endpoint
The mean composite endpoint score in the ICT-guided-DMS
roup of −0.63 was not signiﬁcantly different from the score of
0.73 in the telemonitoring group (mean difference 0.1; 95% CI:
0.67 +0.82, p = 0.39) (Table 3). In total, 8% of the patients (n = 14)
ad the worst possible score of −6 (6 patients in the ICT-guided-
MS group and 8 patients in the telemonitoring group). In total, 27%
f the patients (n = 47) had the best possible score of +2 (19 patients
n the ICT-guided-DMS group and 28 patients in the telemonitoring
roup), with no statistical differences between the groups (p = 0.39).
.3. Secondary endpoints
.3.1. Mortality
All-cause mortality in the ICT-guided-DMS group was 12%
n = 10) and in the telemonitoring group 15% (n = 14), p = 0.27
Table 3). The analyses of time to death showed a hazard-ratio (HR)
f 1.25 (95% CI 0.52–3.00, p = 0.62). At the end of the follow-up, the
otal number of days lost to death was 156 days (range 114–206)
or the ICT-guided-DMS group and 128 days (range 84–217) for
he telemonitoring group (p = 0.52). Kaplan Meier survival analy-
CABG = coronary artery bypass graft; PCI = percutaneous coronary interven-
tion; ICD = internal cardiac deﬁbrillator; NT-pro-BNP = N-terminal prohormone
of  brain natriuretic peptide; eGFR = estimated globular ﬁltration rate: ACE-
inhibitor = angiotensine converting enzyme inhibitor.
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Table  3
Primary and secondary outcomes: composite endpoint score and the separate components of the composite endpoint (n = 177).
ICT DMS  n = 83 ICT DMS  with TM n = 94 CI 95% p-Value
Primary endpoint
Composite endpoint −0.63± 2.37 −0.73± 2.59 -0.67 +0.82 0.39
Secondary endpoints
Mortality 10 (12) 14 (15) −0.14 +0.07 0.27
Re-admission HF 23 (28) 25 (27) −0.12 +0.14 0.87
Change in HR-QoL −14.63 ± 25.14 −13.97 ± 22.31 −8.68 +7.36 0.63
Note: variables were tested one-sided.
Values are given as mean ± SD or number (percentage).
ICT DMS = ICT-guided-disease management system with computer decision support.
ICT DMS with TM = ICT-guided-disease management system with computer decision support and telemonitoring.
Table  4
Number of patients with hospitalizations, number of hospitalizations, number of
outpatient visits and change in HR-QoL (n = 177).
ICT DMS
n = 83
ICT DMS  with
TM n = 94
p-Value
Number of patients with hospitalizations n(%)
All-cause hospitalization 41 (49) 48 (51) 0.78
Cardiovascular-related hospitalizations 15 (18) 17 (18) 0.90
Heart failure-related hospitalizations 23 (28) 25 (27) 0.87
Total number of hospitalizations
All cause 76 96 0.58
Cardiovascular-related 23 19 0.87
Heart failure-related 35 37 0.93
Total number of visits to outpatient clinics (median, IQR)
All-cause 7 (4–12) 6.5 (4–9) 0.28
Heart failure-related 4 (0–6) 2 (0–5) 0.02
Change in HR-QoL 0.71
Improvement ≥20 units 21 (25) 30 (32)
Improvement 10–19 units 14 (17) 7 (7)
No  improvement 13 (16) 18 (19)
Worsening 14 (17) 1 (15)
Not  availablea 21 (25) 25 (27)
Note: values are given as number (percentage) or median (25–75th percentiles).
Variables were tested two-sided.
ICT DMS  = ICT-guided-disease management system with computer decision support.
ICT  DMS  with TM = ICT-guided-disease management system with computer decision
support and telemonitoring.
HR-QoL: health-related quality of life.
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Table 5
Bootstrap simulations (5000 replications of the trial data) to estimate the conﬁdence
intervals surrounding the incremental costs (2.5th and 97.5th percentile) of the
interventions.
Costs ICT-DMS ICT-DMS with TM Difference CI 95%
Intervention D 37a D 1766b D 1729 Constant
Re-admission D 3213 D 2427 D 786 −2875 +1525
Out-of-hospital care D 1152 D 1642 D 490 −1297 +2880
Outpatient clinic D 603 D 530 D 73 −261 +110
Total D 5006 D 6366 D 1360 −2263 +5221
Note: ICT-DMS = ICT-guided-disease management system with computer decision
support.
ICT-DMS with TM = ICT-guided-disease management system with computer deci-QR= interquartile range.
a Of n = 46, in total 24 patients have died.
is did not show a statistically signiﬁcant difference between both
nterventions (log rank 2 = 0.025, p = 0.88).
.3.2. Readmission
Readmission for HF in the ICT-guided-DMS group was  28%
n = 23) versus 27% (n = 25) in the telemonitoring group. All-cause
eadmission was 49% (n = 41) in the ICT-guided-DMS group and
1% (n = 48) for the telemonitoring group. The differences were
on-signiﬁcant between both groups (Tables 3 and 4).
.3.3. Change in HR-QoL
At 9 months the mean change in score was −15 units in the ICT-
uided-DMS group versus −14 units in the telemonitoring group
95% CI: −8.7 +7.4, p = 0.63) (Table 3). The HR-QoL was  improved
ith ≥20 units in 29% (n = 51) of the patients (21 patients in the ICT-
uided-DMS group and 30 patients in the telemonitoring group). In
otal 12% (n = 21) improved between 10 and 19 units (14 patients
n the ICT-guided-DMS group versus 7 patients in the telemoni-
oring group). In total 35% of the patients did not improve or had
orse HR-QoL at the end of the study, with no differences between
oth groups (Table 4). Regarding both sub-scores of the MLHFQ, no
igniﬁcant differences were seen between the groups.sion support and telemonitoring.
a Software.
b Software, telemonitoring devices and the handling of incoming data.
3.3.4. HF-outpatient clinic visits
The median number of visits to the HF-outpatient clinic was 4 for
the ICT-guided-DMS group versus 2 for the telemonitoring group
(p < 0.02) (Table 4). To any outpatient clinic a median of approxi-
mately 7 visits for both groups was  observed (p = 0.28).
3.3.5. Cost analysis
The mean total costs was D 5006 per patient for the ICT-guided-
DMS group and D 6366 per patient for the telemonitoring group
(Table 5). Incremental costs were D 1360 in favour of patients in
the ICT-guided-DMS group. In this scenario the costs for outpatient
visits were D 530 for the telemonitoring group versus D 603 for the
ICT-guided-DMS. Hospital admissions were D 3213 for ICT-guided-
DMS  and D 2427 for the telemonitoring group. In both groups, the
highest proportion of costs consisted of costs for admissions to
a hospital ward. Costs made outside the hospital (GP, dietician,
physiotherapist visits, home care and nursing home [day care, and
admissions]) were D 1152 in the ICT-guided-DSM group and D 1642
in the telemonitoring group. The major cost driver in this cate-
gory was nursing home admissions. The handling of the incoming
telemonitoring data (alerts, viewing the ICT-guided-DMS, making
telephone calls to patients, reporting the action/intervention and
performing follow-up) was estimated at 12 h for each patient for
the total study period, which was  calculated to be D 364 based on
salary of the nurses.
4. Discussion
In this study we found no additional beneﬁt from adding
telemonitoring to an ICT-guided-DMS with CDSS with regard to
the composite endpoint score; all-cause mortality, HF-readmission
and change in HR-QoL. We  expected to ﬁnd a difference of 0.8,
however we  found a difference of only 0.1. An explanation for this
absence of effect could be that the study population was relatively
“healthy” compared to other HF-studies with a comparable patient
population [27], making a signiﬁcant or clinical difference for
5 l of Me
f
h
o
n
a
t
p
r
(
t
i
b
M
w
a
o
s
e
r
b
a
n
t
s
m
t
i
t
r
p
m
b
t
b
t
p
l
r
a
a
i
w
n
h
a
e
w
i
H
i
T
p
a
l
w
m
a
t
w
p
[
w8 I. Kraai et al. / International Journa
urther improvement in outcome rather difﬁcult. Only 16 patients
ad more than 1HF-readmission (9%), and a relative large number
f patients (31%) was newly diagnosed with HF and therefore did
ot have a history of frequent readmissions. Frequent readmissions
re known as unfavourable for outcome [28,29], and it is known
hat newly diagnosed patients stay in a stable condition for a
eriod after they receiving diagnosis and care. Also the mortality
ate in our study was relatively low (13%) and almost all patients
96%) received only scheduled visits to the HF-clinic, indicating
hat there was no need for acute care for worsening HF. Although
n both groups the HR-QoL increased, no differences in score
etween baseline and 9 months was seen between both groups.
oreover, it might be possible that the effect of the intervention
as not large enough to be able to discriminate.
To ﬁnd an effect of telemonitoring on mortality, readmissions
nd, HR-QoL probably requires a more deﬁned and coherent group
f patients that could beneﬁt from this new intervention [30]. It
eems reasonable to assume that other variables such as age, socio-
conomic status or severity of the disease in terms of frequent
eadmissions before starting with telemonitoring might affect the
eneﬁt of telemonitoring, perhaps more than we initially calculated
nd deﬁned in the study protocol. However, previous studies do
ot show speciﬁc proﬁles of patients who could beneﬁt more from
elemonitoring, with the exception for patients with depressive
ymptoms [30].
We found a very high adherence among patients with the tele-
onitoring system during the entire study period, which shows
hat our telemonitoring system was well tolerated by the patient
n comparison with systems used in other studies [19,30]. Fur-
hermore there were issues with adherence by nurses, especially
egarding to the up-titration of HF-medication during the follow-up
eriod in both groups. The CDSS functionality for up-titrating HF-
edication was experienced as difﬁcult, which might be reﬂected
y the relatively low percentage of prescribed ACE-inhibitor used at
he end of the follow-up period. Although the percentage of Beta-
lockers and Mineralocorticoid receptor antagonists are conform
he observed percentages in the EURO Heart survey II study [31], the
ercentage of ACE-inhibitors at the end of the study (59% vs. 60%) is
ower than the observed 80% in the EURO Heart survey II. The main
eason for the lack of use of the CDSS was that the usability and
cceptability were considered poor, primarily due to organization-
nd system-related barriers, which are known as major obstacles
n applying CDSS in healthcare [32–34].
A known personal-related barrier to use a CDSS is a lack of trust,
hich was also observed in some participating hospitals where HF
urses were not allowed to titrate medication themselves due to
esitations of the cardiologists. Finally, the lack of use was also
ttributed to the fact that the CDSS was not integrated into the
xisting electronic patient record and therefore caused additional
ork.
Despite the fact that we could not ﬁnd a difference in outcome
n favour of the telemonitoring group, we found that the number of
F-related visits to the outpatient HF-clinic was statistically signif-
cant lower compared to patients who did not use telemonitoring.
his difference in HF-related outpatient HF-clinic visits was partly
rotocol-driven; patients in the telemonitoring group were only
llowed to visit the cardiologist of HF nurse in case of an abso-
ute need for intervention. Moreover, this indicates also that it
as not necessary to schedule more HF-related visits when tele-
onitoring is being used. The outcome in terms of readmission
nd mortality was similar in both groups. Importantly in this con-
ext, the overall patient adherence of using telemonitoring at home
as very high (the telemonitoring devices were used in 95% of the
atients during the whole study period) compared to other studies
19,30] in which patient adherence of using telemonitoring overall
as not higher than 30–40% or that patient adherence compliancedical Informatics 85 (2016) 53–60
rates decreased after adding blood pressure measurement to daily
weighing [35]. This indicates that the devices used for this study,
combined with the protocol of daily measurements, were very well
accepted by patients. Furthermore, it was explained to the patients
that the telemonitoring measurements would only be reviewed
once a day by the HF nurse, namely in the morning after a cer-
tain time and in case of a deviation of the predeﬁned ranges the
HF nurse would contact the patient within 2 h. This deﬁned time-
range for the use of telemonitoring prevented that the HF nurse
needed to be available during the whole day and outside ofﬁce
hours. This time-range was also applicable in the weekends. There-
fore the HF nurse could schedule the contacts (if necessary) with
the patients in the morning during their normal work routine and
it was  not too much of a workload in the weekends. This prevented
an increased work load for the HF-nurse and the perception of the
patient that the telemonitoring measurements were continuously
monitored [13].
4.1. Practical implications
Taking into consideration the advances and possibilities of
telemonitoring and the limited increase in costs (D 1360), an inter-
vention with telemonitoring might be an option for caregivers.
For patients who do not have direct or difﬁcult access to a HF-
outpatient clinic (e.g., long distance to travel, the inability of a
patient to visit the HF outpatient clinic) or in case of prevent-
ing regular HF-related visits to the HF-outpatients clinic just for
up-titration of medication or assessment of physical condition,
telemonitoring could be a safe and efﬁcient alternative for visit-
ing the HF-outpatient clinic. Telemonitoring could be a signiﬁcant
tool for re-organizing HF-care to be more efﬁcient, a necessity due
to the understaffed care of a growing and aging population.
4.2. Limitations
Despite an extended inclusion period combined with an adjust-
ment of the study protocol, we were not able to include the number
of patients needed as calculated. This could have inﬂuenced the
outcome in terms of a lack of sample strength. However, the calcu-
lated p-values did not show a trend or ‘near’ signiﬁcance. In addition
there were no numerical differences between both groups indicat-
ing that a larger population would probably not make a difference
in outcome. In the design of the study, a cost effectiveness anal-
ysis and/or cost consequence analysis was  planned. The planned
analyses were not performed since no difference in primary and
secondary clinical endpoints were found, therefore we only per-
formed a cost minimization analysis. This study was designed as
a clinical study, therefore some technical aspects might be under-
exposed. Finally, we have no information on how many patients
were not eligible for this study because this was not part of the
protocol.
5. Conclusions
ICT-guided disease management in combination with telemon-
itoring, used in the follow-up of HF-patients, did not affect the
primary (composite) endpoint of mortality, HF-readmission and
HR-QoL, nor the separated individual outcomes of this composite
endpoint. However, we demonstrated that telemonitoring is safe
and can reduce HF-related visits to the HF-outpatient clinic, keep-
ing HF-care accessible. Costs however were D 1360,- higher with
telemonitoring. The adherence of patients in using telemonitor-
ing was  very high, indicating that the devices used for this study,
in combination with daily measurements, were well accepted
I. Kraai et al. / International Journal of Me
Summary points
What was already known on the topic of the study:
- On a caregiver level, cardiologists and HF-nurses have high
expectations of telemonitoring by expecting it to improve
quality of care, reduce costs and to improve patients’ Health-
Related Quality of Life (HR-QoL) by increasing feelings of
control and empowerment of the patient.
- On a population level, results regarding reduction in hospi-
talization and mortality rates by using telemonitoring in HF
patients compared to usual care, are ambiguous.
What this study added to our knowledge:
- It is safe to use telemonitoring and it can reduce HF-related
visits to the HF-outpatient clinic, keeping HF-care accessible.
However the costs were &z.euro;1360,- higher with telemon-
itoring.
- The adherence of patients using telemonitoring was very
high indicating that the devices used in combination with
daily measurements were well accepted by patients.
- We  found no additional beneﬁt from adding telemonitoring
to an ICT-guided-DMS with CDSS with regard to the compos-
ite endpoint score; all-cause mortality, HF-readmission and
change in HR-QoL.
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